moderate in severity

See: mitigate
References in periodicals archive ?
The CHMP positive opinion is supported by data from the global Phase 3 psoriasis program evaluating more than 2,000 patients with moderate to severe plaque psoriasis across four pivotal Phase 3 studies.1-3 Across all four studies, ultIMMA-1, ultIMMa-2, IMMhance and IMMvent, all co-primary and ranked secondary endpoints were met, achieving a significantly higher response of clear or almost clear skin (Static Physicians Global Assessment sPGA 0/1 and Psoriasis Area and Severity Index PASI 90) compared to ustekinumab, adalimumab and placebo at week 16 and up to week 52 (depending on study design).1-3 The most frequently reported adverse reactions were upper respiratory infections, which occurred in 13 percent of patients.5 Most reported adverse reactions were mild or moderate in severity.5
Most reported adverse reactions were mild or moderate in severity. The CHMP positive opinion is a scientific recommendation for marketing authorization to the European Commission, which will review it and issue a Commission decision, valid in all member states of the European Union, as well as Iceland, Liechtenstein and Norway.
64% (Table 1) The severity of skin lesions by using PASI and GEA scores respectively showed that the majority of psoriasis patients were moderate in severity (54%) and majority of acne patients were mild (34%) to moderate (32%) in severity.
CCH was well-tolerated in the actively-treated subjects with most adverse events being mild to moderate in severity and primarily limited to the local injection area.
Full browser ?